Fundies.
English

APRICUS BIOSCIENCES, INC.

EDGAR
APRI Report (type unavailable) · filed 2024-09-25

226 filing records in this dataset, filed from 1997-05-15 to 2024-09-25. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments
Watchlist

Latest quarter

Revenue

376 thousand Unit_Standard_USD_PUk3E8pjJE2B_S43yd6oPw

2024 Q2 · Unit_Standard_USD_PUk3E8pjJE2B_S43yd6oPw

Exact inputs and evidence
  • Revenue: 376000 Unit_Standard_USD_PUk3E8pjJE2B_S43yd6oPw Source

Operating margin

-834.84%

2024 Q2 · %

Exact inputs and evidence
  • Operating Income: -3139000 Unit_Standard_USD_PUk3E8pjJE2B_S43yd6oPw Source
  • Revenue: 376000 Unit_Standard_USD_PUk3E8pjJE2B_S43yd6oPw Source
Cash and cash equivalents
30.5 million USD Source
Exact value

30511000 USD

Long-term debt including current maturities
10.1 million Unit_Standard_USD_PUk3E8pjJE2B_S43yd6oPw Source
Exact value

10100000 Unit_Standard_USD_PUk3E8pjJE2B_S43yd6oPw

Shares outstanding
3.32 million Unit_Standard_shares_vRvyNZTsKE2XLCzyK_brNQ Source
Exact value

3322045 Unit_Standard_shares_vRvyNZTsKE2XLCzyK_brNQ

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Capital expenditure

0 USD

2017-01-01 – 2017-12-31

Exact inputs and evidence
  • Capital expenditure: 0 USD · 2017-01-01 – 2017-03-31 Source
  • Capital expenditure: 0 USD · 2017-01-01 – 2017-06-30 Source
  • Capital expenditure: 0 USD · 2017-01-01 – 2017-03-31 Source
  • Capital expenditure: 0 USD · 2017-01-01 – 2017-09-30 Source
  • Capital expenditure: 0 USD · 2017-01-01 – 2017-06-30 Source
  • Capital expenditure: 0 USD · 2017-01-01 – 2017-12-31 Source
  • Capital expenditure: 0 USD · 2017-01-01 – 2017-09-30 Source

Company performance

Up to ten complete financial years · consolidated figures

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2024-09-25.

Financial data available through: 2023-12-31.

Coverage by financial measure
  • Revenue: 1 of 11 periods available· newest 2023-12-31
  • Operating income: 2 of 11 periods available· newest 2023-12-31
  • Net income: 2 of 11 periods available· newest 2023-12-31
  • Operating cash flow: 2 of 11 periods available· newest 2023-12-31
  • Capital expenditure: 5 of 11 periods available· newest 2017-12-31
  • Total assets: Multiple units; comparison withheld· newest 2023-12-31
  • Total liabilities: Multiple units; comparison withheld· newest 2023-12-31
  • Current assets: Multiple units; comparison withheld· newest 2023-12-31
  • Current liabilities: Multiple units; comparison withheld· newest 2023-12-31
  • Cash and cash equivalents: 8 of 11 periods available· newest 2020-12-31
  • Long-term debt including current maturities: 1 of 11 periods available· newest 2023-12-31
  • Shares outstanding: Multiple units; comparison withheld· newest 2023-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

  • Net income

    +Unit_Standard_USD_KOQJFyFPhUqVaXLPpMvblA 35.65 million

    Prior period

    −Unit_Standard_USD_KOQJFyFPhUqVaXLPpMvblA 73.53 million

    –

    Current period

    −Unit_Standard_USD_KOQJFyFPhUqVaXLPpMvblA 37.88 million

    –

    Exact inputs and evidence

    -37882000 − -73534000 = 35652000 Unit_Standard_USD_KOQJFyFPhUqVaXLPpMvblA

    -73534000 Unit_Standard_USD_KOQJFyFPhUqVaXLPpMvblA · 2022-01-01 – 2022-12-31

    Inspect prior input Prior source

    -37882000 Unit_Standard_USD_KOQJFyFPhUqVaXLPpMvblA · 2023-01-01 – 2023-12-31

    Inspect current input Current source
    Share or cite

    The citation records this snapshot. The page link may show a newer release later.

  • Operating cash flow

    +Unit_Standard_USD_KOQJFyFPhUqVaXLPpMvblA 37.69 million

    Prior period

    −Unit_Standard_USD_KOQJFyFPhUqVaXLPpMvblA 61.6 million

    –

    Current period

    −Unit_Standard_USD_KOQJFyFPhUqVaXLPpMvblA 23.91 million

    –

    Exact inputs and evidence

    -23912000 − -61604000 = 37692000 Unit_Standard_USD_KOQJFyFPhUqVaXLPpMvblA

    -61604000 Unit_Standard_USD_KOQJFyFPhUqVaXLPpMvblA · 2022-01-01 – 2022-12-31

    Inspect prior input Prior source

    -23912000 Unit_Standard_USD_KOQJFyFPhUqVaXLPpMvblA · 2023-01-01 – 2023-12-31

    Inspect current input Current source
    Share or cite

    The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Revenue, Capital expenditure.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2023 2023-01-01 – 2023-12-31

  • Revenue Unit_Standard_USD_KOQJFyFPhUqVaXLPpMvblA 2.2 million 100% of revenue
  • Operating costs Derived Unit_Standard_USD_KOQJFyFPhUqVaXLPpMvblA 42.7 million 1,938% of revenue
  • Operating income −Unit_Standard_USD_KOQJFyFPhUqVaXLPpMvblA 40.5 million −1,838% of revenue
  • Tax, interest and other Derived −Unit_Standard_USD_KOQJFyFPhUqVaXLPpMvblA 2.62 million −119% of revenue
  • Net income −Unit_Standard_USD_KOQJFyFPhUqVaXLPpMvblA 37.88 million −1,720% of revenue

Cash

  • Operating cash flow −Unit_Standard_USD_KOQJFyFPhUqVaXLPpMvblA 23.91 million −1,085% of revenue
  • Capital expenditure Unavailable An input is unavailable.
  • Free cash flow Derived Unavailable An input is unavailable.

Share of revenue by period

  • Net income
  • Tax, interest and other
  • Operating costs
  • 2023 Operating loss: operating costs were 1,938% of revenue.
Values and sources
Revenue breakdown by annual reporting period
PeriodRevenueOperating costsOperating incomeTax, interest and otherNet incomeFree cash flowSource
2023 2023-01-01 – 2023-12-312203000 42702000 Derived -40499000 -2617000 Derived -37882000 Unavailable
Source

Amounts are exact, in Unit_Standard_USD_KOQJFyFPhUqVaXLPpMvblA.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

Unit_Standard_USD_KOQJFyFPhUqVaXLPpMvblA 2.2M 2023
Revenue historyRevenue reported for each complete financial period. Values are shown by financial reporting period. Open Values and sources below for the exact observations and evidence.2.4M1.8M1.2M594.8K0.02023
Values and sources
Revenue values and source evidence
PeriodSeriesValue(Unit_Standard_USD_KOQJFyFPhUqVaXLPpMvblA)Source evidence
2023Revenue2203000

Revenue growth

Change in revenue from the same financial period one year earlier.

Not enough comparable data to show this history.
Values and sources
Revenue growth values and source evidence
PeriodSeriesValueSource evidence
2023Year over yearNo prior comparable period

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -1,838.4% 2023
Net margin -1,719.6% 2023
Profit margins historyOperating income, net income and free cash flow as a share of revenue. Values are shown by financial reporting period. Open Values and sources below for the exact observations and evidence.147%-386%-919%-1,452%-1,985%2023
  • Operating margin
  • Net margin
  • Free cash flow margin
Values and sources
Profit margins values and source evidence
PeriodSeriesValueSource evidence
2023Operating margin-1,838.4%
2023Net margin-1,719.6%
2023Free cash flow marginNot reported

Operating cash flow

Cash generated by the company’s normal business operations.

Unit_Standard_USD_KOQJFyFPhUqVaXLPpMvblA -23.9M 2023
Operating cash flow historyCash generated by the company’s normal business operations. Values are shown by financial reporting period. Open Values and sources below for the exact observations and evidence.1.9M-5.0M-12.0M-18.9M-25.8M2023
Values and sources
Operating cash flow values and source evidence
PeriodSeriesValue(Unit_Standard_USD_KOQJFyFPhUqVaXLPpMvblA)Source evidence
2023Operating cash flow-23912000

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

Not enough comparable data to show this history.
Values and sources
Free cash flow values and source evidence
PeriodSeriesValue(Unit_Standard_USD_KOQJFyFPhUqVaXLPpMvblA)Source evidence
2023Free cash flowUnavailable

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

Not enough comparable data to show this history.
Values and sources
Liabilities to assets values and source evidence
PeriodSeriesValueSource evidence
2023-12-31Liabilities / assetsNot reportedNo source recorded

Current assets to current liabilities

Current assets divided by current liabilities.

Not enough comparable data to show this history.
Values and sources
Current assets to current liabilities values and source evidence
PeriodSeriesValueSource evidence
2023-12-31Current assets / current liabilitiesNot reportedNo source recorded

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
PeriodNet incomeOperating cash flowCapital expenditureFree cash flow
2022 2022-01-01 – 2022-12-31
−Unit_Standard_USD_KOQJFyFPhUqVaXLPpMvblA 73.53 million
Exact value

Exact value: -73534000 Unit_Standard_USD_KOQJFyFPhUqVaXLPpMvblA

2022-01-01 – 2022-12-31: -73534000 Unit_Standard_USD_KOQJFyFPhUqVaXLPpMvblA Inspect Net Income Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−Unit_Standard_USD_KOQJFyFPhUqVaXLPpMvblA 61.6 million
Exact value

Exact value: -61604000 Unit_Standard_USD_KOQJFyFPhUqVaXLPpMvblA

2022-01-01 – 2022-12-31: -61604000 Unit_Standard_USD_KOQJFyFPhUqVaXLPpMvblA Inspect Operating Cash Flow Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

Unavailable Not reported for this period.
Unavailable

Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.

2023 2023-01-01 – 2023-12-31
−Unit_Standard_USD_KOQJFyFPhUqVaXLPpMvblA 37.88 million
Exact value

Exact value: -37882000 Unit_Standard_USD_KOQJFyFPhUqVaXLPpMvblA

2023-01-01 – 2023-12-31: -37882000 Unit_Standard_USD_KOQJFyFPhUqVaXLPpMvblA Inspect Net Income Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−Unit_Standard_USD_KOQJFyFPhUqVaXLPpMvblA 23.91 million
Exact value

Exact value: -23912000 Unit_Standard_USD_KOQJFyFPhUqVaXLPpMvblA

2023-01-01 – 2023-12-31: -23912000 Unit_Standard_USD_KOQJFyFPhUqVaXLPpMvblA Inspect Operating Cash Flow Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

Unavailable Not reported for this period.
Unavailable

Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

226 filings · 3,834 latest values · 3,834 originally reported values

Dataset published . Source filing dates and reporting periods are shown separately.

Identifiers: 0001017491, 1017491, APRI, SEEL, edgar:1017491

Also known as APRICUS BIOSCIENCES, INC., NEXMED INC, SEELOS THERAPEUTICS, INC., SEELOS THERAPEUTICS, INC., SEELOS THERAPEUTICS, INC., Seelos Therapeutics, Inc.